Key Takeaways
- • Palliser Capital launched a public activist campaign on September 14, 2026, demanding Recordati's board withdraw support for Respighi BidCo's €51.29-per-share tender offer, citing material undervaluation of the Italian pharmaceutical company.
- • The hedge fund is pushing for a minimum price of €60 per share, representing a 17% increase over the current consortium bid, and argues that all four independent directors unanimously rejected the offer based on Rothschild & Co.'s fairness opinion finding the bid unfair to minority shareholders.
- • Palliser identifies severe governance conflicts: six non-independent directors with ties to the CVC and GBL consortium controlling the process have overridden unanimous opposition from independent directors, creating structural bias in the transaction.
- • The activist letter highlights minority shareholder coercion risk, arguing that shareholders face pressure to tender or face illiquid, delisted securities with reduced protections following a subsequent delisting merger, effectively removing exit optionality.
- • This represents an event-driven minority protection play in European pharma, targeting a leveraged consortium acquisition where independent fiduciaries have already flagged valuation and process defects.
Summary
Palliser Capital publicly escalated its opposition to Recordati S.p.A.'s proposed acquisition by the CVC and GBL consortium on September 14, 2026, releasing a letter dated September 1 that calls for the board to reject Respighi BidCo's €51.29-per-share tender offer. The hedge fund argues the bid materially undervalues the Italian pharmaceutical company and demands the consortium raise its offer to a minimum of €60 per share—representing implicit upside of approximately 17% from the current bid price.
Palliser's critique rests on three substantive pillars. First, the valuation floor of €60 is anchored to Rothschild & Co.'s fairness opinion, which concluded the €51.29 offer is unfair to minority shareholders. Notably, all four of Recordati's independent directors unanimously recommended rejection of the transaction, signaling serious internal skepticism about deal merit. Second, Palliser highlights governance defects in the transaction process itself. Six directors with material conflicts—either direct ties to the consortium or financial interests in the deal's completion—have driven board support despite the unanimous opposition of all independent directors. This structural imbalance raises material questions about fiduciary accountability and the integrity of the recommendation process.
Third, the activist identifies a minority shareholder coercion dynamic embedded in the deal structure. Shareholders who decline to tender face the prospect of illiquid, delisted securities with diminished legal protections following a subsequent delisting merger. This framework effectively constrains shareholder choice by creating asymmetric risk: acceptance of the consortium's bid or acceptance of forced illiquidity in a post-delisting environment with weakened minority safeguards. Palliser frames this as a pressure mechanism that lacks the voluntary character essential to fair minority treatment.
The letter represents a conventional activist intervention in a leveraged consortium acquisition—a category of deal where independent directors have already flagged both valuation and process concerns. Palliser's public campaign is distinct from its concurrent activism in other sectors and is grounded in documented fiduciary skepticism and fairness analysis, rather than market speculation. The outcome will depend on whether the consortium opts to revise its offer, whether minority shareholders mobilize through other channels, and whether regulatory or corporate governance dynamics in Italy generate additional friction on the transaction.
Palliser's critique rests on three substantive pillars. First, the valuation floor of €60 is anchored to Rothschild & Co.'s fairness opinion, which concluded the €51.29 offer is unfair to minority shareholders. Notably, all four of Recordati's independent directors unanimously recommended rejection of the transaction, signaling serious internal skepticism about deal merit. Second, Palliser highlights governance defects in the transaction process itself. Six directors with material conflicts—either direct ties to the consortium or financial interests in the deal's completion—have driven board support despite the unanimous opposition of all independent directors. This structural imbalance raises material questions about fiduciary accountability and the integrity of the recommendation process.
Third, the activist identifies a minority shareholder coercion dynamic embedded in the deal structure. Shareholders who decline to tender face the prospect of illiquid, delisted securities with diminished legal protections following a subsequent delisting merger. This framework effectively constrains shareholder choice by creating asymmetric risk: acceptance of the consortium's bid or acceptance of forced illiquidity in a post-delisting environment with weakened minority safeguards. Palliser frames this as a pressure mechanism that lacks the voluntary character essential to fair minority treatment.
The letter represents a conventional activist intervention in a leveraged consortium acquisition—a category of deal where independent directors have already flagged both valuation and process concerns. Palliser's public campaign is distinct from its concurrent activism in other sectors and is grounded in documented fiduciary skepticism and fairness analysis, rather than market speculation. The outcome will depend on whether the consortium opts to revise its offer, whether minority shareholders mobilize through other channels, and whether regulatory or corporate governance dynamics in Italy generate additional friction on the transaction.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.